Furthermore, several ongoing clinical trials are investigating TCR-T specific to WT1 (NCT00620633, NCT01758328) as well as preferentially expressed antigen in melanoma (PRAME) (NCT02743611, NCT03503968), both of which have exhibited overexpression patterns in solid tumors, ALL, AML, and MDS [80,81]. The gene discussed is WT1; the disease is acute myeloid leukemia.